The influence of maternal insulin-dependent diabetes on fetal nuchal translucency thickness and first-trimester maternal serum biochemical makers of aneuploidy

被引:35
|
作者
Spencer, K
Cicero, S
Atzei, A
Otigbah, C
Nicolaides, KH
机构
[1] Harold Wood Hosp, Clin Biochem Dept, Prenatal Screening Unit, Romford RM3 0BE, Essex, England
[2] Kings Coll Hosp London, Harris Birthright Res Ctr Fetal Med, London, England
[3] Harold Wood Hosp, Dept Obstet, Romford, Essex, England
关键词
prenatal screening; trisomy; 21; nuchal translucency; free beta-human chorionic gonadotrophin; pregnancy associated plasma protein-A;
D O I
10.1002/pd.1229
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Objective To evaluate the influence of maternal insulin dependent diabetes mellitus (IDDM) on maternal serum free beta-hCG, PAPP-A and fetal nuchal translucency (NT), thickness at 11 to 13(+6) weeks of gestation in a large cohort of women screened prospectively for chromosomal anomalies. Methods Information on maternal IDDM status, maternal serum biochemical marker levels and fetal NT were collected from the prenatal screening computer records in two first-trimester screening centres. In total the control group included 33 301 pregnancies of which 16 366 had NT and maternal serum biochemistry results and 16 305 with NT only. The IDDM group included 195 pregnancies of which 79 had NT and maternal serum biochemistry results and 127 with NT only. The median maternal weight corrected free beta-hCG and PAPP-A, expressed as multiple of the median (MoM), and fetal NT, expressed as delta values, in the IDDM and non-IDDM groups were compared. Results There were no significant differences between the IDDM and non-IDDM groups in median maternal weight corrected free beta-hCG (IDDM 0.87 MoM, 95% Confidence Interval 0.75 to 1.16 MoM, non-IDDM 1.00 MoM), median maternal weight corrected PAPP-A (IDDM 1.02 MoM, 95% Confidence Interval 0.83 to 1.05 MoM, non-IDDM 1.01 MoM), or mean delta NT (IDDM 0.0358 mm, non-IDDM 0.0002 mm). Conclusions In pregnancies with maternal IDDM, first-trimester screening for chromosomal defects does not require adjustments for the measured fetal NT. However, more data are required before the possible reduction in maternal serum free beta-hCG and the reduction of PAPP-A suggested by the published world series can be considered sufficiently important to take into account in the calculation of risks for chromosomal defects. Copyright (c) 2005 John Wiley & Sons, Ltd.
引用
收藏
页码:927 / 929
页数:3
相关论文
共 50 条
  • [41] Does diurnal variation affect the first trimester fetal aneuploidy screening test biochemical parameters of fetuses with normal nuchal translucency?
    Karsli, Mehmet Fatih
    Cakmak, Bulent
    Seckin, Kerem Doga
    Yilmaz, Elif Akkas
    Akgul, Gurcan
    Togrul, Cihan
    Kucukozkan, Tuncay
    JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE, 2016, 29 (11): : 1808 - 1811
  • [42] The impact of fetal gender on first trimester nuchal translucency and maternal serum free β-hCG and PAPP-A MoM in normal and trisomy 21 pregnancies
    Cowans, Nicholas J.
    Stamatopoulou, Anastasia
    Mainz, Nerea
    Spencer, Kevin
    Nicolaides, Kypros H.
    PRENATAL DIAGNOSIS, 2009, 29 (06) : 578 - 581
  • [43] The efficiency of first-trimester serum analytes and maternal characteristics in predicting fetal growth disorders
    Goetzinger, Katherine R.
    Singla, Ashima
    Gerkowicz, Sabrina
    Dicke, Jeffrey M.
    Gray, Diana L.
    Odibo, Anthony O.
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2009, 201 (04) : 412.e1 - 412.e6
  • [44] FIRST-TRIMESTER MATERNAL SERUM ALPHA-FETOPROTEIN AS A MARKER FOR FETAL CHROMOSOMAL DISORDERS
    VANLITH, JMM
    PRENATAL DIAGNOSIS, 1994, 14 (10) : 963 - 971
  • [45] Discordant results between fetal cell-free DNA in maternal plasma and chorionic villus sampling in a first-trimester fetus with increased nuchal translucency and megacystis
    Sepulveda, W.
    ULTRASOUND IN OBSTETRICS & GYNECOLOGY, 2014, 44 (03) : 369 - 369
  • [46] First and second trimester maternal serum markers for prenatal aneuploidy screening: An update on the adjustment factors for race, smoking, and insulin dependent diabetes mellitus
    Huang, Tianhua
    Bellai-Dussault, Kara
    Meng, Lynn
    Hull, Danna
    Howley, Heather
    Reszel, Jessica
    Lanes, Andrea
    Walker, Mark
    Armour, Christine M.
    Okun, Nan
    Dougan, Shelley D.
    CLINICAL BIOCHEMISTRY, 2023, 118
  • [47] THE IMPLEMENTATION OF FIRST-TRIMESTER SCANNING AT 10-13 WEEKS GESTATION AND THE MEASUREMENT OF FETAL NUCHAL TRANSLUCENCY THICKNESS IN 2 MATERNITY UNITS
    PANDYA, PP
    GOLDBERG, H
    WALTON, B
    RIDDLE, A
    SHELLEY, S
    SNIJDERS, RJM
    NICOLAIDES, KH
    ULTRASOUND IN OBSTETRICS & GYNECOLOGY, 1995, 5 (01) : 20 - 25
  • [48] Is There a Relationship Between First-Trimester Aneuploidy Screening Serum Biomarker Values and Nuchal Translucency Measurements and the Development of Retinopathy of Prematurity (ROP) in Premature Infants?
    Kucuk, Mehmet Fatih
    Savas, Hasan Basri
    Suren, Elcin
    Erol, Muhammet
    Yaprak, Lutfiye
    Sabanci, Senol
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (10)
  • [49] First-trimester contingent screening for trisomies 21, 18 and 13 by fetal nuchal translucency and ductus venosus flow and maternal blood cell-free DNA testing
    Kagan, K. O.
    Wright, D.
    Nicolaides, K. H.
    ULTRASOUND IN OBSTETRICS & GYNECOLOGY, 2015, 45 (01) : 42 - 47
  • [50] First-Trimester Maternal Serum Adiponectin/Leptin Ratio in Pre-Eclampsia and Fetal Growth
    de Knegt, Victoria E.
    Hedley, Paula L.
    Eltvedt, Anna K.
    Placing, Sophie
    Wojdemann, Karen
    Shalmi, Anne-Cathrine
    Rode, Line
    Kanters, Jorgen K.
    Sundberg, Karin
    Tabor, Ann
    Lausten-Thomsen, Ulrik
    Christiansen, Michael
    LIFE-BASEL, 2023, 13 (01):